FRONTIER BIOTECHNOLOGIES Inc.

  • IR
  • IR
  • Career
  • Career Opportunities
  • Student Programs
  • Contact Us
  • Contact Us
  • Social Media

     
    Home>News
    Keith AlcornPublished: 28 October 2016A new fusion inhibitor, albuvirtide, under development in China, combined with a boosted protease inhibitor, proved just as effective as a triple regimen of lopinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors (NRTIs) in treatment-experienced...
  • 2019-01-25  15:47:42
  • details>

    Develop Innovative Therapies to Better Human Lives